Patents by Inventor Masaaki Sawa

Masaaki Sawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10793575
    Abstract: An oxoisoquinoline compound of the following formula: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the oxoisoquinoline compound or salt; and a method for treating B-cell lymphoma comprising administering the oxoisoquinoline compound or salt to a patient.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: October 6, 2020
    Assignee: CARNA BIOSCIENCES, INC.
    Inventors: Wataru Kawahata, Takao Kiyoi, Takayuki Irie, Tokiko Asami, Masaaki Sawa, Shigeki Kashimoto
  • Publication number: 20200055848
    Abstract: Herein disclosed are compounds, compositions, kits, and methods of treating cancers using 7-azaindolyl furanone/thiophene derivatives. These derivatives inhibit serine-threonine kinase Cdc7, a recognized anticancer target affecting DNA replication. Further, the compounds disclosed herein possess potent inhibitory activity in the presence of adenosine triphosphate (ATP), demonstrate significant kinase selectivity, and offer advantages over known Cdc7 inhibitors with prolonged half-life and inhibitory effects.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Inventors: Takayuki IRIE, Ayako SAWA, Masaaki SAWA, Tokiko ASAMI, Yoko FUNAKOSHI, Chika TANIYAMA
  • Patent number: 10538521
    Abstract: The present invention provides a novel 2,4,6-substituted pyrimidine derivative, which is a compound represented by formula (I) (in the formula, ring A is a 6-membered heteroaryl group having at least one N atom optionally substituted with R1, R2, and R3; Z is an optionally substituted alkoxy group, an optionally substituted amino group, an optionally substituted heterocycloalkyl group, or an optionally substituted heteroaryl group; and R1, R2, and R3 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyloxy group, an optionally substituted heterocycloalkyloxy group, an optionally substituted phenoxy group, an optionally substituted amino group, a nitro group, and a hydroxy group) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: January 21, 2020
    Assignees: CARNA BIOSCIENCES, INC., THE KITASATO INSTITUTE
    Inventors: Masaaki Sawa, Yuko Asamitsu, Yuko Uno, Satoshi Omura, Kazuhiko Otoguro, Masato Iwatsuki, Aki Ishiyama, Rei Hokari
  • Publication number: 20190359616
    Abstract: The present invention provides with an oxoisoquinoline derivative represented by the formula (I) (in the formula, Q and R1 are as defined in the description) or a pharmaceutically acceptable salt thereof, which is useful as a Bruton's kinase inhibitor for treating cancer, B-cell lymphoma, chronic lymphocytic leukemia and the like.
    Type: Application
    Filed: November 24, 2017
    Publication date: November 28, 2019
    Applicant: CARNA BIOSCIENCES, INC.
    Inventors: Wataru KAWAHATA, Takao KIYOI, Takayuki IRIE, Tokiko ASAMI, Masaaki SAWA, Shigeki KASHIMOTO
  • Publication number: 20190345154
    Abstract: The present invention provides a novel 2,4,6-substituted pyrimidine derivative, which is a compound represented by formula (I) (in the formula, ring A is a 6-membered heteroaryl group having at least one N atom optionally substituted with R1, R2, and R3; Z is an optionally substituted alkoxy group, an optionally substituted amino group, an optionally substituted heterocycloalkyl group, or an optionally substituted heteroaryl group; and R1, R2, and R3 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyloxy group, an optionally substituted heterocycloalkyloxy group, an optionally substituted phenoxy group, an optionally substituted amino group, a nitro group, and a hydroxy group) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 25, 2017
    Publication date: November 14, 2019
    Applicants: CARNA BIOSCIENCES, INC., THE KITASATO INSTITUTE
    Inventors: Masaaki SAWA, Yuko ASAMITSU, Yuko UNO, Satoshi OMURA, Kazuhiko OTOGURO, Masato IWATSUKI, Aki ISHIYAMA, Rei HOKARI
  • Publication number: 20190269227
    Abstract: The present disclosure relates to a method for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates. The disclosed method incorporates alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars into a cellular glycoconjugate. A chemical probe comprising an azide group and a visual probe or a fluorogenic probe is used to label the alkyne-derivatized sugar-tagged glycoconjugate. In one aspect, the chemical probe binds covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and is visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA or confocal microscopy, and mass spectrometry.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Inventors: Chi-Huey WONG, Tsui-Ling HSU, Sarah R. HANSON, Masaaki SAWA
  • Patent number: 10317393
    Abstract: Methods for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates are disclosed. Alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars are incorporated into cellular glycoconjugates. Chemical probes comprising an azide group and a visual or fluorogenic probe and used to label alkyne-derivatized sugar-tagged glycoconjugates are disclosed. Chemical probes bind covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and are visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA, confocal microscopy, and mass spectrometry.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: June 11, 2019
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Tsui-Ling Hsu, Sarah R. Hanson, Masaaki Sawa
  • Patent number: 9974795
    Abstract: Provided is a pharmaceutical composition comprising a Cdc7 inhibitor and an M phase promoter. In particular, the Cdc7 inhibitor contained in the pharmaceutical composition is a furanone derivative represented by formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, A is —COOR1 or a hydrogen atom; R1 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic condensed ring, or an optionally substituted amino group. Alternatively, R2 and R3 may, together with the nitrogen atoms bonding the same, form an optionally substituted heterocycle or optionally substituted heterocyclic condensed ring. R4 is a hydrogen atom or halogen atom.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: May 22, 2018
    Assignee: CARNA BIOSCIENCES, INC.
    Inventors: Yoko Funakoshi, Chika Tanaka, Tokiko Asami, Masaaki Sawa
  • Publication number: 20180106780
    Abstract: Methods for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates are disclosed. Alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars are incorporated into cellular glycoconjugates. Chemical probes comprising an azide group and a visual or fluorogenic probe and used to label alkyne-derivatized sugar-tagged glycoconjugates are disclosed. Chemical probes bind covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and are visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA, confocal microscopy, and mass spectrometry.
    Type: Application
    Filed: October 10, 2017
    Publication date: April 19, 2018
    Inventors: Chi-Huey WONG, Tsui-Ling HSU, Sarah R. Hanson, Masaaki SAWA
  • Patent number: 9816981
    Abstract: Methods for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates are disclosed. Alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars are incorporated into cellular glycoconjugates. Chemical probes comprising an azide group and a visual or fluorogenic probe and used to label alkyne-derivatized sugar-tagged glycoconjugates are disclosed. Chemical probes bind covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and are visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA, confocal microscopy, and mass spectrometry.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: November 14, 2017
    Assignee: ACADEMIA SINICA
    Inventors: Masaaki Sawa, Chi-Huey Wong, Tsui-Ling Hsu, Sarah Hanson
  • Patent number: 9682961
    Abstract: The present invention provides a quinazoline derivative represented by the following formula (I): wherein R1 and R2 represent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/?-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: June 20, 2017
    Assignees: CARNA BIOSCIENCES, INC., NATIONAL CANCER CENTER
    Inventors: Hideki Moriyama, Masaaki Sawa, Yuko Uno, Shigeki Kashimoto, Tesshi Yamada
  • Patent number: 9656995
    Abstract: The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, R2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group, A represents a nitrogen atom or C—R3, R3 represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and R4 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: May 23, 2017
    Assignee: CARNA BIOSCIENCES, INC.
    Inventors: Wataru Kawahata, Tokiko Asami, Masaaki Sawa, Yuko Asamitsu, Takayuki Irie, Takahiro Miyake, Takao Kiyoi
  • Publication number: 20170065609
    Abstract: Provided is a pharmaceutical composition comprising a Cdc7 inhibitor and an M phase promoter. In particular, the Cdc7 inhibitor contained in the pharmaceutical composition is a furanone derivative represented by formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, A is —COOR1 or a hydrogen atom; R1 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic condensed ring, or an optionally substituted amino group. Alternatively, R2 and R3 may, together with the nitrogen atoms bonding the same, form an optionally substituted heterocycle or optionally substituted heterocyclic condensed ring. R4 is a hydrogen atom or halogen atom.
    Type: Application
    Filed: January 26, 2015
    Publication date: March 9, 2017
    Inventors: Yoko FUNAKOSHI, Chika TANAKA, Tokiko ASAMI, Masaaki SAWA
  • Publication number: 20160264555
    Abstract: The present invention provides a quinazoline derivative represented by the following formula (I): wherein R1 and R2 represent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/?-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.
    Type: Application
    Filed: December 5, 2014
    Publication date: September 15, 2016
    Applicants: NATIONAL CANCER CENTER, CARNA BIOSCIENCES, INC.
    Inventors: Hideki MORIYAMA, Masaaki SAWA, Yuko UNO, Shigeki KASHIMOTO, Tesshi YAMADA
  • Publication number: 20160221991
    Abstract: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, either of Z1 and Z2 represents carbon atom and the other is nitrogen atom, or both of the Z1 and Z2 represent nitrogen atoms, Q is selected from a structure (a) and (b) described below: wherein R2 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, R3 represents a hydrogen atom or a halogen atom, Y represents a nitrogen atom or a carbon atom, and the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 12, 2014
    Publication date: August 4, 2016
    Inventors: Takahiro MIYAKE, Wataru KAWAHATA, Tokiko ASAMI, Masaaki SAWA
  • Publication number: 20160207906
    Abstract: To provide a novel 2,6-diaminopyrimidine derivative by the following formula (I): A 2,6-diaminopyrimidine derivative is represented by the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, Z1 and Z2 represent carbon atoms, or either 1 or 2 of the Z1 and Z2 represent nitrogen atoms, Q is selected from a structure (a) or (b) described below: R2 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, R3 represents a hydrogen atom or a halogen atom, Y represents a nitrogen atom or a carbon atom, and the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond.
    Type: Application
    Filed: September 1, 2014
    Publication date: July 21, 2016
    Inventors: Wataru KAWAHATA, Tokiko ASAMI, Masaaki SAWA, Takayuki IRIE
  • Publication number: 20160168122
    Abstract: The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, R2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group, A represents a nitrogen atom or C—R3, R3 represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and R4 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 15, 2014
    Publication date: June 16, 2016
    Inventors: Wataru KAWAHATA, Tokiko ASAMI, Masaaki SAWA, Yuko ASAMITSU, Takayuki IRIE, Takahiro MIYAKE, Takao KIYOI
  • Patent number: 9102637
    Abstract: The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: August 11, 2015
    Assignees: CARNA BIOSCIENCES, INC., NATIONAL CANCER CENTER
    Inventors: Masaaki Sawa, Hideki Moriyama, Tesshi Yamada, Miki Shitashige, Yusuke Kawase, Yuko Uno
  • Patent number: RE46815
    Abstract: To provide a novel furanone derivative, and a medicine including the same.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: May 1, 2018
    Assignee: Carna Biosciences, Inc.
    Inventors: Takayuki Irie, Ayako Sawa, Masaaki Sawa, Tokiko Asami, Yoko Funakoshi, Chika Tanaka
  • Patent number: RE48140
    Abstract: To provide a novel furanone derivative, and a medicine including the same.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: August 4, 2020
    Assignee: CARNA BIOSCIENCES, INC.
    Inventors: Takayuki Irie, Ayako Sawa, Masaaki Sawa, Tokiko Asami, Yoko Funakoshi, Chika Tanaka